Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — Merger or Acquisition (July 2026)
15 slides from Processa Pharmaceuticals's merger presentation, Jul 28, 2026
Slide 1: Webcast Presentation
Webcast Presentation July 28, 2026 1
Slide 2: Disclaimers
Disclaimers The information in this Presentation has been prepared by Processa Pharmaceuticals, Inc. ("Processa") and Vidya Therapeutics, Inc. ("Vidya" and, together with Processa and each of Processa's subsidiaries, the "combined company") and contains information pertaining to the business and ope
Slide 3: Processa Announces Acquisition of Vidya Therapeutics
Processa Announces Acquisition of Vidya Therapeutics • Acquisition of Vidya was structured as a stock-for-stock transaction whereby all of Vidya’s outstanding equity interests were exchanged for a combination of shares of Processa common stock and newly created Series A non-voting convertible prefer
Slide 4: Advancing BTK Inhibitor Therapies for Immune-Mediated Diseases
Advancing BTK Inhibitor Therapies for Immune-Mediated Diseases A potentially best-in-class, oral, once-daily BTK inhibitor (BTKi), engineered to improve on the efficacy and safety of early-generation programs. A clinical-stage biotechnology 3 Phase 1 2027-28 company focused on immune-system Parallel
Slide 5: Vidya Pipeline
Vidya Pipeline Pipeline-in-a-product optionality from a single optimized molecule Compound Indication Phase 1 Phase 2 Phase 3 Anticipated Next Milestones Phase 2 initiation H2’26 Food Allergy Phase 2 PoC data H2’27 VT-7208 Phase 2 initiation H2’26 CSU (BTKi) Phase 2 PoC data H1’28 Phase 2 initiation
Slide 6: The Opportunity
The Opportunity Clinically Validated Multiple Value-Creation Clear Unmet Need / Mechanism Paths Expected Large Addressable Markets CSU: >1.7M U.S. patients1 BTK inhibition established Parallel development in CSU, • Uncontrolled on H1 across autoimmune diseases food allergy and relapsing anti-histami
Slide 7: BTK is a Compelling Target: A Central Node in Adaptive and Innate Immunity
BTK is a Compelling Target: A Central Node in Adaptive and Innate Immunity B-Cells (Adaptive) Central immune signaling node Myeloid Cells (Innate) BCR FcR BCR signaling drives: BTK’s dual role: FcR signaling drives: • Proliferation • Links adaptive and innate • Myeloid cell activation • Antigen pres
Slide 8: Strong and Differentiated Preclinical Profile Supports Advancement into the Clinic
Strong and Differentiated Preclinical Profile Supports Advancement into the Clinic • Potent in vitro and in vivo with strong Strong CNS Penetration peripheral and CNS target engagement • Consistent efficacy observed across disease models • Clean metabolic profile with predictable PK VT7208 • Low liv
Slide 9: VT-7208 Phase 1 Study Design Enabled Efficient Dose Escalation and Translational Readouts
VT-7208 Phase 1 Study Design Enabled Efficient Dose Escalation and Translational Readouts Single Ascending Dose Multiple Ascending Dose 60 mg 10 mg QD x 7d SAFETY SRC SRC 20 mg >95% BTK TO 20 mg QD x 7d x 24 hrs Food Effect 5 mg Cohort 20 mg 6 VT-7208:2 PBO per cohort; food cohort 8 VT-7208 • Primar
Slide 10: VT-7208's Phase 1 Results Demonstrated Favorable Safety Profile and Tolerability Profile
VT-7208’s Phase 1 Results Demonstrated Favorable Safety Profile and Tolerability Profile Parameter SAD Food Cohort MAD (QDx7) 5 mg 20 mg 60 mg 20 mg 10 mg 20 mg SAEs 0/6 0/6 0/6 0/8 0/6 0/6 1/6 Grade 3 or higher 0/6 0/6 0/6 0/8 0/6 Blood draw site pain 1/6 1/8 Related AEs 0/6 0/6 0/6 0/6 Headache (G
Slide 11: VT-7208's Predictable PK Supports Low, Once-Daily Oral Dosing
VT-7208’s Predictable PK Supports Low, Once-Daily Oral Dosing Single Ascending Dose Multiple Ascending Dose CSF 5 mg 10 mg 20 mg 10 mg IC50 Human derived iPSC derived microglia 60 mg 20 mg • Predictable PK profile, consistent with preclinical characterization • Near dose-proportional increases in ex
Slide 12: VT-7208 Demonstrated Robust and Sustained BTK Target Engagement at ≥ 5 mg/day
VT-7208 Demonstrated Robust and Sustained BTK Target Engagement at ≥ 5 mg/day Single Ascending Dose Multiple Ascending Dose Near complete target occupancy sustained 100% BTK occupancy at steady state; for 24 hours across doses confirmed by phospho-BTK signaling ≥95% occupancy sustained up to 48 hour
Slide 13: Robust and Sustained Inhibition of pBTK Demonstrated Modulation of Signaling Pathway
Robust and Sustained Inhibition of pBTK Demonstrated Modulation of Signaling Pathway • MAD cohort results • SAD cohort underway The sustained inhibition of pBTK demonstrated the potential for durable pharmacodynamic activity, reinforcing confidence in the molecule’s therapeutic and dosing strategy 1
Slide 14: Why this Program, Why Now?
Why this Program, Why Now? Phase 1 Complete, Advancing Phase 2 POC studies in Food Allergy, CSU, & Relapsing MS with data expected in 2027 and 2028 Target / Asset Preclinical Translational Clinical Strategic Validated biology Low risk of Predictable PK Well-defined Capital-efficient hepatotoxicity s
Slide 15: Thank You
Thank You info@vidyatx.com Webcast Presentation July 2026 15
Processa Pharmaceuticals — Merger or Acquisition (July 2026) on 6ix